Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?
暂无分享,去创建一个
Brent D. Cameron | P. Brown | M. Mehta | J. Buatti | H. Shih | L. Gaspar | P. Sneed | K. Beal | A. Sahgal | S. Braunstein | D. Tandberg | J. Kirkpatrick | James B. Yu | E. Lou | Jing Li | A. Aizer | D. Roberge | H. Aoyama | P. Sperduto | S. Myrehaug | A. Attia | R. Shanley | D. Cagney | M. Chuong | P. Fang | V. Chiang | Supriya K. Jain | J. Molitoris | Cheng-Chia Wu | N. Lockney | L. Masucci | H. Saito | W. Breen | D. Shi | Jessica R Parkhurst | T. Wang
[1] P. Brown,et al. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool , 2018, Neuro-oncology.
[2] P. Brown,et al. Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. , 2018, International journal of radiation oncology, biology, physics.
[3] James X. Sun,et al. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 , 2018, Cancer.
[4] Wen Jiang,et al. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.
[5] J. Pignon,et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] P. Brown,et al. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. , 2017, International journal of radiation oncology, biology, physics.
[7] P. Brown,et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.
[8] D. Sargent,et al. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.
[9] D. Sargent,et al. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.
[10] Ruth E Langley,et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.
[11] P. Brown,et al. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.
[12] Volker W Stieber,et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.
[13] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[14] A. Mehrabi,et al. Brain metastasis from gastrointestinal cancers: a systematic review , 2014, International journal of clinical practice.
[15] P. Brown,et al. Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. , 2012, International journal of radiation oncology, biology, physics.
[16] Stef van Buuren,et al. Flexible Imputation of Missing Data , 2012 .
[17] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Labianca,et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.
[19] L. Collette,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[21] P. Brown,et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.
[22] K. Hess,et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.
[23] A. Jimeno,et al. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Hiroki Shirato,et al. Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .
[25] J. Posner,et al. Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.
[26] S. Bartelt,et al. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. , 2004, World journal of gastroenterology.
[27] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[28] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[29] C. Atreya,et al. Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[30] R. Chamberlain,et al. Gastrointestinal Cancer and Brain Metastasis Outcomes and Management , 2015 .
[31] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .